Specificity Proteins (Sp) and Cancer.
Specificity Proteins (Sp) and Cancer.
复制标题
DOI：
10.3390/ijms24065164
复制
发表时间：
2023-03-08
影响因子：
5.6
通讯作者：
中科院分区：
文献类型：
--
作者：
特异性蛋白（Sp）转录因子（TF）Sp1、Sp2、Sp3和Sp 4在癌细胞中表现出结构和功能相似性，对Sp1的广泛研究表明，它是多种肿瘤类型患者的负面预后因素。本文就Sp1、Sp3和Sp 4在肿瘤发生发展中的作用及其对促癌因子和通路的调控作一综述。此外，还讨论了与非编码RNA的相互作用以及靶向Sp转录因子的药物的开发。对正常细胞转化为癌细胞系的研究表明，在大多数细胞模型中，这种转化过程伴随着Sp1水平的增加，而在肌细胞转化为横纹肌肉瘤时，Sp1和Sp3都增加，但Sp 4没有增加。在敲低研究中研究了癌细胞系中Sp1、Sp3和Sp 4的促癌功能，其中每个单独Sp TF的沉默降低了癌症生长、侵袭和诱导的细胞凋亡。个别Sp TF的沉默不被其他两个补偿，并且得出结论，Sp1、Sp3和Sp 4是非癌基因成瘾基因的实例。这一结论得到了Sp TF与非编码microRNA和长非编码RNA相互作用的结果的加强，其中Sp1有助于Sp/非编码RNA的促癌功能。现在有许多诱导Sp1、Sp3和Sp 4下调/降解的抗癌剂和药物的实例，但特异性靶向SpTF的药物的临床应用尚未使用。应考虑在联合治疗中应用靶向Sp TF的药物，以提高治疗效果并降低毒副作用。
The specificity protein (Sp) transcription factors (TFs) Sp1, Sp2, Sp3 and Sp4 exhibit structural and functional similarities in cancer cells and extensive studies of Sp1 show that it is a negative prognostic factor for patients with multiple tumor types. In this review, the role of Sp1, Sp3 and Sp4 in the development of cancer and their regulation of pro-oncogenic factors and pathways is reviewed. In addition, interactions with non-coding RNAs and the development of agents that target Sp transcription factors are also discussed. Studies on normal cell transformation into cancer cell lines show that this transformation process is accompanied by increased levels of Sp1 in most cell models, and in the transformation of muscle cells into rhabdomyosarcoma, both Sp1 and Sp3, but not Sp4, are increased. The pro-oncogenic functions of Sp1, Sp3 and Sp4 in cancer cell lines were studied in knockdown studies where silencing of each individual Sp TF decreased cancer growth, invasion and induced apoptosis. Silencing of an individual Sp TF was not compensated for by the other two and it was concluded that Sp1, Sp3 and Sp4 are examples of non-oncogene addicted genes. This conclusion was strengthened by the results of Sp TF interactions with non-coding microRNAs and long non-coding RNAs where Sp1 contributed to pro-oncogenic functions of Sp/non-coding RNAs. There are now many examples of anticancer agents and pharmaceuticals that induce downregulation/degradation of Sp1, Sp3 and Sp4, yet clinical applications of drugs specifically targeting Sp TFs are not being used. The application of agents targeting Sp TFs in combination therapies should be considered for their potential to enhance treatment efficacy and decrease toxic side effects.
登录
查看更多内容
影响因子：
3.8
作者：
Chintharlapalli S;Papineni S;Lei P;Pathi S;Safe S
通讯作者：
Safe S
影响因子：
3.7
作者：
Cheng Y;Imanirad P;Jutooru I;Hedrick E;Jin UH;Rodrigues Hoffman A;Leal de Araujo J;Morpurgo B;Golovko A;Safe S
通讯作者：
Safe S
影响因子：
5.6
作者：
通讯作者：
--
影响因子：
2.8
作者：
Chen, Yi-Ting;Tsai, Hung-Pei;Kwan, Aij-Lie
通讯作者：
Kwan, Aij-Lie
影响因子：
3
作者：
Chen, Kai-Yun;Zhu, Shu-Guang;Duan, Xiao-Peng
通讯作者：
Duan, Xiao-Peng